Most drug therapy regimens expose the human body to a foreign chemical for several hours to days and even years. Hence, before a new drug is approved by regulatory agencies, extensive safety studies are conducted to ensure that exposure to the drug will not cause undesirable effects in patients. A major cause for adverse events and drug attrition is cardiovascular toxicity 1, 2 . Drug developers have attempted to identify these issues earlier in medicine development to reduce risks to human volunteers in clinical trials and costs of pursuing the development of unsafe
drugs. In 2005, the International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) issued a guideline for the examination of new drug candidates in a series of in vitro and in vivo tests to assess their arrhythmogenic potential 3 . Inhibition of the delayed rectifier potassium current (I Kr ) in the heart has been linked to the majority of drug-induced arrhythmias. As a result, in vitro safety testing has been focused on acute drug effects on I Kr or hERG, the potassium channel that underlies I Kr 4 . The development of high-throughput automated methods to measure hERG currents in heterologous expression systems has fueled the emphasis of in vitro testing on I Kr early in drug discovery and perhaps prevented the development of new medicines by discarding compounds prematurely. This testing paradigm has been challenged over the past several years with the realization that verapamil and a number of other drugs which inhibit I Kr at therapeutic concentrations do not cause arrhythmias in patients. Verapamil has compensatory effects on other cardiac ion channels such that action potential duration (APD) is not affected by this drug and it is safe to administer to patients 5, 6 . In addition, arsenic trioxide, pentamidine and other drugs associated with a prolonged QT interval and cardiac arrhythmias do not block I Kr acutely but instead inhibit its trafficking to the cell surface when applied for prolonged (overnight or longer) periods of time 7 . More recently, Lu and colleagues 8 showed that prolonged application of nilotinib and related anticancer drugs that potential 3 . Inhibition of the delayed rectifier potassium current (I Kr ) in the heart h h has as b bee ee en n n li li link nk nke ed o the majority of drug-induced arrhythmias. As a result, d in vitro safety testing has been focused on n a a acu cu cute te te d d dru ru rug g g ef ffe fe fec ct cts on I Kr or hERG, the potassi si ium um um channel that un u u de erl rl rlie ie ies I Kr 4 . The developmen of f h h hig i h-throug ghp hp hpu ut t a aut u utom om mat at ated ed ed m met et tho ho hod ds s t to m m mea a asur re hE hERG RG RG c c cur r rre ren n nts s in in h h het ter erol ol olo og ogou ous s s e ex exp pres es essi sio on on y yst st stem em ms s ha ha as s s fu f fuel eled ed d t the he e e e emp mpha ha hasi si is s s of of of in in v v vit it tro ro ro t t tes s sti ti t ng ng ng o o on I I Kr Kr e e ea a arly ly y i in n n dr dr drug ug u di is isco co ove ve very ry ry a a an nd nd p p per r rha hap p ps Yang and colleagues also found that effects on late sodium currents were not limited to dofetilide or terfenadine 8 . They reported that other I Kr blockers also increased I Na-L in CHO cells transfected with Nav1.5. D-sotalol and E-4031, both methanesulfonanilides like dofetilide, increased I Na-L after prolonged exposure. They also observed increased late sodium currents, although to a lower extent, with three unrelated drugs, the antipsychotics haloperidol and thioridazine and the antibiotic erythromycin. Finally, moxifloxacin and verapamil did not alter the amplitude of I Na-L . This range of effects on late sodium currents could significantly contribute to the variety of pro-arrhythmic activities of these I Kr blockers. Increased late sodium currents are a known cause of cardiac arrhythmias. Several mutations in SCN5A, the gene encoding the cardiac sodium channel Nav1.5, underlie the long QT syndrome LQT3. These mutations lead to various levels of late sodium currents, all very small relative to peak current amplitudes ( 3%) but large enough to disrupt action potentials and cause arrhythmias. This paper may show us the tip of the iceberg with regard to the effects of prolonged drug exposure on cardiac action potentials and their underlying ionic currents. Additional studies are Yang and colleagues also found that effects on late sodium currents were e no no ot t l li limi mi mite te ted d d to to dofetilide or terfenadine 8 . They reported that other I Kr blockers also increased I warranted to determine the prevalence of drug effects on late sodium currents. Most early safety pharmacology studies on cardiac ion channels are performed on automated electrophysiology instruments. The latter however generally do not have the sensitivity to measure late sodium current amplitudes reliably (I Na-L < 0.5% of peak sodium currents in the transfected CHO cells described in this study). Therefore manual patch clamp studies would be necessary to accurately detect changes in late sodium channel currents after prolonged drug exposure. Testing the effects of prolonged drug exposure on the PI3K signaling pathway (e.g. Akt phosphorylation) could be a first step to identify potential modulators of late sodium currents. However, drugs could increase I Na-L and cause heart rhythm abnormalities through direct interactions with the channel or through other pathways. These effects would be missed if drugs were only tested in PI3K pathway assays. The alpha-1 adrenergic receptor antagonist and proarrhythmic drug alfuzosin was shown to increase I Na-L in human embryonic kidney 293 cells 10 . It would be interesting to determine whether these effects are sensitive to PIP3. Finally, Yang and colleagues showed that ATX II, a peptide toxin that binds to sodium channels, increased I Na-L in a PIP3-independent manner.
The need to examine the effects of drug candidates on multiple cardiac ion channels and review the current testing paradigm is the focus of a recently initiated public-private project called Comprehensive in vitro Proarrhythmia Assay (CiPA) 11 . This project proposes, in part, the examination of drug effects on various cardiac channels and their integration in silico by computer models of human cardiac electrophysiology, with the aim to propose a new paradigm for the assessment of the pro-arrhythmic potential of new drugs. However most cardiac ion channel assays and modeling efforts examine acute exposure to drugs and do not consider prolonged or chronic effects 12 . For example they do not incorporate effects on channel hrough other pathways. These effects would be missed if drugs were only tested d d in n n PI PI I3K 3K 3K
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